Roper Industries, Inc. (now identified in the request as Roper Technologies, Inc.) — FY2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013; filed February 21, 2014. This is an annual report, not a quarterly filing. The filing reports the company under the name Roper Industries, Inc.
Business context
Diversified manufacturer and software/services provider operating in Medical and Scientific Imaging, RF Technology, Industrial Technology, and Energy Systems and Controls. The company’s strategy emphasizes operating improvement and acquisitions. 2013 acquisitions included Managed Health Care Associates (MHA; acquired May 1 for approximately $1.0 billion) and Advanced Sensors (acquired October 4 for $54 million).
Financial performance
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Net sales | $3.238 billion | $2.993 billion | +8% |
| Gross profit / margin | $1.883 billion / 58.1% | $1.672 billion / 55.8% | Margin +2.3 percentage points |
| Operating income / margin | $842.4 million / 26.0% of sales | $757.6 million / 25.3% | Income +11% |
| Net earnings / margin | $538.3 million / 16.6% | $483.4 million / 16.1% | +11% |
| Diluted EPS | $5.37 | $4.86 | +10% |
| Operating cash flow | $802.6 million | $677.9 million | +18% |
| Capital expenditures | $42.5 million | $38.4 million | — |
Sales growth comprised 7% from acquisitions and 1% organic growth. Orders rose 11.9% to $3.35 billion; year-end backlog increased 11.4% to $1.055 billion. Foreign-currency movements reduced 2013 sales by less than 1% and operating profit by less than 1%.
Segment trends: Medical and Scientific Imaging sales rose 28%, mainly from acquisitions; organic sales declined 1%. RF Technology sales increased 7%. Energy Systems and Controls sales increased 1%, largely from acquisitions, with mixed organic demand. Industrial Technology sales declined 2%, including weakness in water metering and materials testing.
Quarterly context: Q4 2013 sales were $889.2 million versus $809.9 million in Q4 2012; net earnings were $165.7 million versus $143.5 million; diluted EPS was $1.65 versus $1.44.
Margins, liquidity, and debt
Gross margin improvement reflected, among other factors, the higher-margin medical business mix and stronger RF Technology performance. Operating margin was pressured in Industrial Technology by lower volume and a $9.1 million warranty charge, but improved in the other three segments. Net interest expense increased 30% to $88.0 million, primarily because of higher average debt balances.
Cash and cash equivalents were $459.7 million at year-end. Total debt was $2.465 billion, up from $2.022 billion; debt was 36.9% of total capital versus 35.4% in 2012. The company reported $1.2 billion of undrawn availability under its $1.5 billion revolving facility, subject to facility terms and letters of credit. It was in compliance with debt covenants. Operational net working capital, defined in the filing as current assets excluding cash less current liabilities excluding debt, was $282 million versus $308 million.
Cash used in investing was $1.116 billion, primarily for acquisitions. Approximate operating cash flow less capital expenditures was $760 million. Cash and short-term investments at foreign subsidiaries totaled $386 million and were considered permanently reinvested; repatriation for domestic use could trigger additional taxes.
Changes, outlook, and notable items
- FY2013 effective tax rate was 28.6%, down from 29.6%; the filing cites tax benefits, including $6 million from the retroactive tax-law extension and a separate $6 million benefit from correcting an immaterial out-of-period tax adjustment. Management expected the rate to increase in 2014 as earnings mix shifted toward higher-tax jurisdictions and the benefit did not recur.
- Management expected positive operating cash flow and debt reduction, while noting that acquisition needs and operating performance could affect the pace. Expected capital expenditures were 1.0%–1.5% of annual sales. The filing provides no specific 2014 revenue or EPS guidance.
- A $9.1 million pretax warranty expense was recorded for replacement of refrigeration valves containing a vendor-supplied component that failed company quality standards; year-end warranty accrual was $14.3 million.
- Goodwill was $4.55 billion, or 56% of total assets. No impairment was recorded, but one RF Technology reporting unit had less than 5% estimated fair-value headroom under the discounted-cash-flow approach; a trade name in an RF unit was also sensitive to assumed sales growth.
- Management stated that ordinary-course legal matters were adequately provided for and were not expected to materially affect results. Potential asbestos-related liabilities could not be determined. Outstanding surety bonds totaled $410 million.
Key risks and investor verification points
- Verify acquisition contribution to growth, MHA’s post-acquisition performance, integration progress, and the eventual purchase-price allocation.
- Assess leverage, refinancing and covenant capacity, interest-rate exposure, and management’s ability to reduce debt while continuing acquisitions. A 1% rise in rates was estimated to increase annual interest cost by $2.5 million on year-end variable-rate borrowings.
- Monitor organic demand and orders by segment, particularly Industrial Technology, and whether backlog converts to revenue as expected.
- Review warranty claims and costs following the refrigeration-valve issue, as well as any developments in product-liability, asbestos, environmental, or other legal contingencies.
- Evaluate goodwill and intangible-asset impairment sensitivity, especially the RF reporting unit with limited valuation headroom; goodwill and other intangible assets together totaled about $6.59 billion.
- Consider foreign-exchange and international-market exposure, acquisition-related cash needs, and the tax consequences of repatriating foreign cash. No customer accounted for 10% or more of company sales.